A new oral medication to treat patients in the early stages of multiple sclerosis has shown considerable promise in two clinical trials, researchers announced.

The medication is on track to become just the third oral drug available to M.S. patients, and potentially the safest and most effective, experts said. The second oral drug, called Aubagio, was approved just last week.

M.S. was virtually untreatable only two decades ago, but today nine “disease modifying” drugs ...

The author of this paper is the same author (Dr. Jack Van Horssen) who found protandim, dietary supplement more effective
than fumurate derivative BG-12.

Could someone remind me of what BG12 is actually?? I know its fumeric acid or something like that but I read somewhere on this forum that it can be synthesised via a supplement but just can't find the post.
Thanks

The latest data on Biogen Idec Inc.'s (BIIB) experimental multiple-sclerosis pill BG-12 show "favorable safety and tolerability" that support the drug's use as a front-line treatment for MS patients, the biotechnology company said.

Details from the "Confirm" study on BG-12 were set for presentation at an American Academy of Neurology conference Tuesday. The drug is currently under review with U.S. and European regulators and could be approved early next year.
Positive data and high ...

Has anybody heard of the drug BG-12..??? Wife had an appointment with her neuro today and is looking to put
her on BG-12. She currently is taking Rebif and doing quite well with the only side affect is the rashes at injection site.
Anyhow, any info would be greatly appreciated.


Thanks,

Bob

Biogen files new drug application (NDA) for BG-12.

http://www.zacks.com/stock/news/70735/B ... alyst+Blog

Biogen Idec (BIIB) recently announced the submission of a new drug application (NDA) for its oral multiple sclerosis candidate, BG-12. The NDA was based on data from the phase III DEFINE and CONFIRM studies which showed that treatment with BG-12 led to a significant reduction in disease activity in multiple sclerosis patients. Moreover, the candidate had a favorable ...

Biogen Idec Inc., a Weston-based biotechnology company known for its multiple sclerosis drugs, said it has submitted a New Drug Application to federal regulators to get approval to market a potential new MS treatment known as BG-12.

In December, Biogen Idec shares hit their high for 2011 after the company released promising results from a clinical trial of BG-12.

BG-12, the company’s designation for dimethyl fumarate, would be taken twice a day in pill ...

Biogen Idec Inc's says its experimental multiple sclerosis drug BG-12 met the main goal of a closely watched clinical trial.

The Weston, Massachusetts-based biotechnology company said that a late-stage trial known as CONFIRM showed that BG-12, when given twice a day, cut the annualized relapse rate in patients with multiple sclerosis by 44 percent at two years versus placebo, and by 51 percent when given three times a day.

Investors had been waiting to ...

Oral MS drug BG-12 significantly reduced MS relapses and disability progression



Biogen Idec BIIB today announced positive data from the Phase 3 DEFINE clinical trial of oral BG-12 (dimethyl fumarate) in people with relapsing-remitting multiple sclerosis (RRMS).

Results showed that 240 mg of BG-12, administered either twice a day (BID) or three times a day (TID), significantly reduced the proportion of patients who relapsed by 49 percent and 50 percent, respectively, at two years ...